TCGA-A8-A06Q-01A-11R-A034-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.460
- OXIDATIVE_PHOSPHORYLATION+0.440
- E2F_TARGETS+0.430
- G2M_CHECKPOINT+0.390
- MTORC1_SIGNALING+0.390
- MYC_TARGETS_V2+0.370
- PROTEIN_SECRETION+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.350
- PEROXISOME+0.280
- FATTY_ACID_METABOLISM+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.630
- ANGIOGENESIS-0.620
- TNFA_SIGNALING_VIA_NFKB-0.570
- HEDGEHOG_SIGNALING-0.530
- IL6_JAK_STAT3_SIGNALING-0.520
- INFLAMMATORY_RESPONSE-0.500
- NOTCH_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.460
- INTERFERON_ALPHA_RESPONSE-0.450
- ALLOGRAFT_REJECTION-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-7955-01A-11R-2187-07 | — | cohortA4 | 0.935 |
| 2 | bbeadeec-bb57-4762-8828-3bd1696748fb | — | — | 0.934 |
| 3 | R6 | — | — | 0.922 |
| 4 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.921 |
| 5 | SRR12202421 | — | — | 0.921 |
| 6 | TCGA-BH-A0H0-01A-11R-A056-07 | — | B | 0.918 |
| 7 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.917 |
| 8 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.915 |
| 9 | BSR_20_0054redo_S62 | — | B | 0.915 |
| 10 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |